Novavax confirmed high levels of vaccine efficacy against both original and variant COVID-19 strains in recent United Kingdom and South Africa trials.
In a press release Thursday, the Gaithersburg-based drug company said its vaccine has shown to provide 100% protection against severe disease, including hospitalizations and deaths. In a Phase 3 trial, Novavax reported a 96.4% efficacy rate against the original COVID-19 strain.
In a Phase 2b trial taking place in South Africa, with efficacy of 55.4% among HIV-negative trial participants in a region where the majority of cases are coronavirus variants.
The company said this confirms interim results from January 2021, adding more backing to support its vaccine’s resistance to COVID-19.
March 11 marked the one-year anniversary that COVID-19 was declared a global pandemic. “With this data in hand, we are even more motivated to advance our vaccine as a potential weapon in the fight to end the suffering caused by COVID-19,” Stanley C. Erck, President and Chief Executive Officer of Novavax said in the press release.
The full press release can be found here.
— Novavax (@Novavax) March 11, 2021